Equity Research Pharmaceutical Preparations

Should You Buy Alterity Therapeutics Limited Stock in 2026?

By CirclFi Research Team · · 8/13 models active

According to the CirclFi Deep Alpha Valuation Engine, Alterity Therapeutics Limited (ATHE) registers a weak Quality of Company score of 2.1/10. At the current price of $4.74, our 13-model framework evaluates whether the stock's discount is sufficient to compensate for high fundamental risks.

The short answer: 4 of 8 CirclFi valuation models project upside for Alterity Therapeutics Limited (ATHE) at $4.74 — the models are evenly split, with a Quality Score of 2.1/10 and Value-Trap risk of —/100. The full bull case, bear case, and risk factors are below. Educational analysis, not financial advice.

Key Takeaways

  • Models are split: 4 bullish vs 4 bearish
  • Quality Score: 2.1/10 — Very Weak — significant concerns
  • Value Trap Risk: —/100 — Not scored
  • Fair Value Range: $0.56 – $22.67 (3938% spread)

Bullish Models

4 / 8

Bearish Models

4 / 8

Quality Score

2.1 /10

Very Weak — significant concerns

Value Trap Risk

— /100
Not scored

Not scored

Model Consensus

8 /13
Active Models

Avg. confidence: 3%

Investment Thesis

The Bull Case

Target: $22.67 (+378.3% upside)

  • According to the CirclFi Deep Alpha Valuation Engine, the gap between the market price of $4.74 and the composite fair value of $6.74 implies +42.1% upside potential.
  • According to the CirclFi Deep Alpha Valuation Engine, the ML Residual Income model targets a fair value of $22.67 (+378.3%), anchoring the bull case with a methodology that provides a differentiated analytical lens.
  • Industry tailwind: therapeutic area leadership could provide meaningful support for Alterity Therapeutics Limited's revenue and margin trajectory in the Pharmaceutical Preparations space.

The Bear Case

Target: $0.56 (-88.2%)

  • According to the CirclFi Quality of Company (QOC) framework, Alterity Therapeutics Limited's score of 2.1/10 signals fundamental weaknesses that could undermine the investment thesis.
  • According to the CirclFi Deep Alpha Valuation Engine, the Regime Cross-Sectional model sees the stock as overvalued with a fair value of $0.56 (-88.2%), suggesting that the market price embeds overly optimistic growth assumptions.
  • According to the CirclFi Deep Alpha Valuation Engine, the wide model spread of +466.5% reflects fundamental divergence on key assumptions (growth, cost of capital) depending on the methodology.
  • Industry headwind: drug pricing legislation represents a meaningful risk for Alterity Therapeutics Limited and its Pharmaceutical Preparations peers.

Peer Benchmarking

AMPH Amphastar Pharmaceut
10.0
AZN AstraZeneca PLC
10.0
CPRX Catalyst Pharmaceuti
10.0
HRMY Harmony Biosciences
10.0
NVO Novo Nordisk A/S
10.0

See full Pharmaceutical Preparations rankings →

Valuation Divergence

Spread

3938%

Fair Value Range

$0.56 – $22.67

A 3938% spread signals high uncertainty. The investment outcome depends heavily on which scenario plays out.

Most Bullish

ML-RIV

$22.67 (+378.3%)

Most Bearish

Regime Cross

$0.56 (-88.2%)

Key Risk Factors

Weak Fundamentals

QOC 2.1/10 signals below-average quality.

Model Disagreement

3938% spread signals high variance in projections.

Macro/Sector Risk

Pharmaceutical Preparations headwinds could affect earnings trajectory.

Model Limitations

Backward-looking models cannot predict disruptions.

Want the full 13-model breakdown?

See every fair value, confidence score, and value trap analysis.

View ATHE Data Page →

The Bottom Line

Alterity Therapeutics Limited at $4.74 is a genuine coin-flip in our framework. The 3–4 bull-bear split across 8 models, +466.5% model spread, and composite fair value of $6.74 (+42.1% avg.) argue for a watchlist position rather than a high-conviction bet. Quality at 2.1/10 adds additional caution to the mix.

These are quantitative model outputs, not investment recommendations. Alterity Therapeutics Limited's future depends on factors — management execution, competitive dynamics, regulatory changes — that no algorithm can fully capture. See all 13 model estimates →

Frequently Asked Questions

Should I buy ATHE stock right now?

Based on CirclFi's multi-model analysis, 4 of 8 models see upside for ATHE at $4.74. The models are divided, which means the investment case depends heavily on your assumptions about Alterity Therapeutics Limited's future. This is not a buy recommendation — see our full disclaimer.

What are the biggest risks of investing in Alterity Therapeutics Limited?

Key risks include: a below-average Quality Score of 2.1/10, indicating fundamental weakness; wide model disagreement (3938% spread), signaling high uncertainty; general market and sector-specific risks affecting Pharmaceutical Preparations companies. Always diversify and consult a financial advisor.

How does ATHE compare to its competitors?

Among Pharmaceutical Preparations peers, ATHE holds a Quality Score of 2.1/10. Comparable companies include AMPH (QOC 10.0), AZN (QOC 10.0), CPRX (QOC 10.0). The relative ranking helps investors identify whether ATHE offers better fundamental quality than alternatives in the same sector.

Is ATHE a good long-term investment?

Long-term investment potential depends on fundamental quality and sustainable competitive advantages. ATHE's Quality Score of 2.1/10 raises concerns about long-term viability without significant operational improvements. Check our full data page for all 13 model estimates.

What price should I buy ATHE at?

CirclFi does not provide target buy prices or price alerts. However, our 8 active models produce fair value estimates ranging from $0.56 to $22.67. At $4.74, the stock trades within the range of model estimates. Many value investors look for a 20-30% margin of safety below intrinsic value before buying.

Want the complete picture?

See all 13 model estimates, confidence scores, and the full valuation table for ATHE.

View ATHE Data Page Full Terminal — $39/mo

Disclaimer: This article is produced by the CirclFi Valuation Engine using quantitative models and is for educational and informational purposes only. It is not financial advice, a buy/sell recommendation, or a solicitation to trade securities. Past performance is not indicative of future results. All data sourced from SEC EDGAR, FRED, and GDELT. Consult a licensed financial advisor before making investment decisions. Full disclaimer →